

Cover Story
ClinicalTrials & Tribulations
By Wenora Johnson, Danielle Ripley-Burgess, Heather Hampel, Folasade (Fola) P. May, Anjee Davis and Richard M. Goldberg
Technological advances are transforming our understanding of cancer, accelerating the evolution of new treatment approaches. In the past decades, researchers deploying new techniques for analyzing DNA have extended our knowledge of inherited genetic abnormalities that can predispose a person to develop colorectal and other cancers.
In Brief


Funding Opportunities
Clinical Roundup


Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says


















